日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Integrated Metabolomics and Lipidomics Analysis Reveals the Mechanism Behind the Action of Chiglitazar on the Protection Against Sepsis-Induced Acute Lung Injury.

代谢组学和脂质组学综合分析揭示了奇格列扎对脓毒症引起的急性肺损伤的保护机制

Lu Liu-Liu, Cao Yu-Li, Lu Zhen-Chen, Wu Han, Hu Shan-Song, Ye Bing-Qing, He Jin-Zhi, Di Lei, Chen Xu-Lin, Liu Zhi-Cheng

A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation

DCN1-UBC12 相互作用的强效小分子抑制剂,可选择性阻断 cullin 3 neddylation

Haibin Zhou, Jianfeng Lu, Liu Liu, Denzil Bernard, Chao-Yie Yang, Ester Fernandez-Salas, Krishnapriya Chinnaswamy, Stephanie Layton, Jeanne Stuckey, Qing Yu, Weihua Zhou, Zhenqiang Pan, Yi Sun, Shaomeng Wang

Discovery of 4-((3'R,4'S,5'R)-6″-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2″-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3″-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development

发现 4-((3'R,4'S,5'R)-6″-氯-4'-(3-氯-2-氟苯基)-1'-乙基-2″-氧代二螺[环己烷-1,2'-吡咯烷-3',3″-吲哚]-5'-甲酰胺基)双环[2.2.2]辛烷-1-羧酸 (AA-115/APG-115):一种具有口服活性的强效小鼠双微体 2 (MDM2) 抑制剂,目前正处于临床开发阶段

Angelo Aguilar, Jianfeng Lu, Liu Liu, Ding Du, Denzil Bernard, Donna McEachern, Sally Przybranowski, Xiaoqin Li, Ruijuan Luo, Bo Wen, Duxin Sun, Hengbang Wang, Jianfeng Wen, Guangfeng Wang, Yifan Zhai, Ming Guo, Dajun Yang, Shaomeng Wang